Search

Your search keyword '"Shad, Aziza"' showing total 22 results
Start Over Author "Shad, Aziza" Search Limiters Full Text
22 results on '"Shad, Aziza"'

4. Training Pediatric Hematologists / Oncologists for Capacity Building in Ethiopia

Author

Hailu, Daniel, primary, Adamu, Haileyesus, additional, Fufa, Diriba, additional, Karimi, Doreen, additional, Alexander, Thomas, additional, Habashy, Catherine, additional, Dotan, Amit, additional, Wali, Rabia M, additional, Kumar, Prasanna N, additional, Bonilla, Miguel, additional, Bekele, Wondwessen, additional, Weitzman, Sheila, additional, Broas, Julie, additional, Korones, David N, additional, and Shad, Aziza T, additional

Published
2019
Full Text
View/download PDF

6. Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Author

Schoch, Laura K, primary, Borrello, Ivan, additional, Fuchs, Ephraim J., additional, Bolanos-Meade, Javier, additional, Huo, Jeffrey Sean, additional, Gojo, Ivana, additional, Wagner-Johnston, Nina, additional, Prince, Gabrielle T, additional, McCurdy, Shannon R., additional, Smith, B. Douglas, additional, DeZern, Amy E., additional, Showel, Margaret M., additional, Loeb, David, additional, Shad, Aziza T., additional, Jones, Richard J, additional, Ambinder, Richard F., additional, and Gladstone, Douglas, additional

Published
2016
Full Text
View/download PDF

12. 800 TGF-β Pathway Members ELF and SMAD3 Are Key Tumor Suppressors in Human Beckwith-Wiedemann Syndrome

Author

Upadhyay, Geeta, primary, Kim, Youngwoo, additional, Yao, Zhixing, additional, Jogunoori, Wilma S., additional, Amin, Rupen, additional, Kreishman, Pete, additional, Zasloff, Michael, additional, Ahmad, Moin, additional, Shad, Aziza, additional, Reddy, Premkumar, additional, Mishra, Bibhutibushan, additional, Weksberg, Rosanna, additional, and Mishra, Lopa, additional

Published
2008
Full Text
View/download PDF

13. Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing

Author

Hope, William W., primary, Seibel, Nita L., additional, Schwartz, Cindy L., additional, Arrieta, Antonio, additional, Flynn, Patricia, additional, Shad, Aziza, additional, Albano, Edythe, additional, Keirns, James J., additional, Buell, Donald N., additional, Gumbo, Tawanda, additional, Drusano, George L., additional, and Walsh, Thomas J., additional

Published
2007
Full Text
View/download PDF

14. Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

Author

Walsh, Thomas J., primary, Adamson, Peter C., additional, Seibel, Nita L., additional, Flynn, Patricia M., additional, Neely, Michael N., additional, Schwartz, Cindy, additional, Shad, Aziza, additional, Kaplan, Sheldon L., additional, Roden, Maureen M., additional, Stone, Julie A., additional, Miller, Alisha, additional, Bradshaw, Susan K., additional, Li, Susan X., additional, Sable, Carole A., additional, and Kartsonis, Nicholas A., additional

Published
2005
Full Text
View/download PDF

20. Lymphocyte Depletion During Treatment With Intensive Chemotherapy for Cancer

Author

Mackall, Crystal L., Fleisher, Thomas A., Brown, Margaret R., Magrath, Ian T., Shad, Aziza T., Horowitz, Marc E., Wexler, Leonard H., Adde, Melissa A., McClure, Linda L., and Gress, Ronald E.

Abstract

Recently we have observed an increased incidence of opportunistic infections in patients treated with intensive chemotherapy for cancer. Because T-cell depletion is associated with similar clinical events in human immunodeficiency virus infection and after bone marrow transplantation, we have analyzed peripheral blood lymphocyte populations in a series of patients during treatment with intensive chemotherapy for cancer. Although neutrophil, monocyte, and platelet numbers consistently recovered to greater than 50% of pretreatment values after each sequential cycle of therapy, lymphocyte numbers did not recover within the same time period. B cells decreased rapidly from a mean value of 149 ± 46/mm3before chemotherapy to 4 ± 1/mm3during chemotherapy (P= .011. CD4+T cells decreased from a mean of 588 ± 76/mm3before chemotherapy to 105 ± 28/mm3during chemotherapy (P=.0002) and CD8+T cells decreased from a mean of 382 ± 41/mm3before chemotherapy to 150 ± 46/mm3during chemotherapy (P= .0009). Natural killer cell numbers did not show significant declines (171 ± 30/ mm3before, 114 ± 24/mm3during, P= .19). Based on the history of opportunistic complications in patients with other disorders who display similar degrees of CD4+T-cell lymphopenia and preliminary observations in this population, immune incompetence could surface as a dose-limiting toxicity for highly dose-intensive chemotherapy regimens.

Published
1994
Full Text
View/download PDF

21. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients

Author

Seibel, Nita L., Shad, Aziza T., Bekersky, Ihor, Groll, Andreas H., Gonzalez, Corina, Wood, Lauren V., Jarosinski, Paul, Buell, Donald, Hope, William W., and Walsh, Thomas J.

Abstract

ABSTRACTThe safety, tolerability, and pharmacokinetics of the liposomal formulation of amphotericin B (L-AMB) were evaluated in 40 immunocompromised children and adolescents. The protocol was an open-label, sequential-dose-escalation, multidose pharmacokinetic study with 10 to 13 patients in each of the four dosage cohorts. Each cohort received daily dosages of 2.5, 5.0, 7.5, or 10 mg of amphotericin B in the form of L-AMB per kg of body weight. Neutropenic patients between the ages of 1 and 17 years were enrolled to receive empirical antifungal therapy or treatment of documented invasive fungal infections. The pharmacokinetic parameters of L-AMB were measured as those of amphotericin B by high-performance liquid chromatography and calculated by noncompartmental methods. There were nine adverse-event-related discontinuations, four of which were related to infusions. Infusion-related side effects occurred for 63 (11%) of 565 infusions, with 5 patients experiencing acute infusion-related reactions (7.5- and 10-mg/kg dosage levels). Serum creatinine levels increased from 0.45 ± 0.04 mg/dl to 0.63 ± 0.06 mg/dl in the overall population (P= 0.003), with significant increases in dosage cohorts receiving 5.0 and 10 mg/kg/day. At the higher dosage level of 10 mg/kg, there was a trend toward greater hypokalemia and vomiting. The area under the concentration-time curve from 0 to 24 h (AUC0–24) values for L-AMB on day 1 increased from 54.7 ± 32.9 to 430 ± 566 μg · h/ml in patients receiving 2.5 and 10.0 mg/kg/day, respectively. These findings demonstrate that L-AMB can be administered to pediatric patients at dosages similar to those for adults and that azotemia may develop, especially in those receiving ≥5.0 mg/kg/day.

Published
2016
Full Text
View/download PDF

22. Childhood cancer presentation and initial outcomes in Ethiopia: Findings from a recently opened pediatric oncology unit.

Author

Hordofa DF, Ahmed M, Birhanu Z, Weitzman S, Broas J, Shad A, Bonilla M, and Alexander TB

Abstract

There were no pediatric oncology centers in southwest Ethiopia prior to 2016. This study aims to describe presenting diagnoses and initial outcomes at Jimma University Medical Center (JUMC), the first pediatric oncology unit (POU) in southwest Ethiopia, provide initial insights into regional pediatric cancer epidemiology, illustrate the rapid growth of pediatric cancer services, and highlight ongoing challenges. We used a retrospective descriptive approach to assess the epidemiologic pattern and initial treatment outcomes of pediatric cancer at JUMC POU from August 2016 through December 2022. During the study period, 749 children were diagnosed with cancer at JUMC. The mean age was 7.2 years (20 days-18 years). Acute lymphoblastic leukemia was the most common diagnosis (16.4%), followed by non-Hodgkin lymphoma (12.4%), Wilms tumor (11.1%), soft tissue sarcoma (8.8%), Hodgkin lymphoma (8.4%), and retinoblastoma (8.3%). Brain tumors accounted for only 2.7% of the diagnoses. Of the 703 patients that were not referred elsewhere, 42% of the patients abandoned treatment, 29% died, 17% completed treatment, and 7% remained on treatment at the time of this assessment. The findings emphasize the growth in the diagnosis and treatment of children with cancer in the southwest region of Ethiopia. The data suggests a different epidemiologic profile of childhood cancer cases diagnosed at the JUMC POU compared to high-income countries and neighbouring countries in Africa. Treatment abandonment remains a barrier to care. Ongoing areas of focus include establishment of a hospital-based cancer registry, reduction of treatment abandonment, improvement of diagnostic capacity, and increased access to advanced supportive care., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Hordofa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results